Business Wire

LR Health & Beauty invests in the support of its sales partners

14.5.2019 14:18:00 EEST | Business Wire | Press release

Share

LR Health & Beauty continuously invests in the development of modern sales concepts which enable the partners to successfully set up and expand their businesses. The company has now launched the innovative tool "LR MyOffice" to support sales partners with their work in the digital LR world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005504/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

LR Health & Beauty invests in the support of its sales partners (Photo: Business Wire)

Transparent, simple and compatible with all devices

In cooperation with the American software provider Exigo, the direct sales company from Ahlen was able to take digitalisation to the next level. Thanks to "LR MyOffice" sales partners can get information on all relevant business figures and activities at a glance – the data is updated around the clock. What turnover have I achieved thus far this month? How are my team members developing? Are there persons in my team who soon celebrate their birthday or jubilee, whom I can congratulate? "LR MyOffice" has the answers and works as a personal assistant. "The programme helps LR partners to better understand their business figures and to control their business activities", says Andreas Friesch, CEO and management spokesman of LR. Furthermore, the tool runs on all terminal devices – not only on the PC at home but also on tablets and smartphones.

Clear activity orientation for new partners and professionals

The special feature of "LR MyOffice" is that every partner sees at first glance what he and his team members have to do to reach the next bonus or career level. Thanks to easy application, even novices manage the tool with ease and are able to quickly manage their LR business independently. The tool box enables profs to exploit opportunities with regard to structure and daily routine even more efficiently. "We were very pleased to partner with LR to leverage our technical expertise and platform, to create the new tool for LR's partners", says Ed Jarrin, President of Exigo.

Positive feedback in the prelaunch phase

The prelaunch phase started last February – from 14 May, the tool will be available for all LR sales partners. "From my point of view, 'LR MyOffice' has already proved its worth. The partners who used the tool in the prelaunch phase are simply impressed", says Friesch contently. In the course of the next few months, new functions will be added to the programme.

LR Health & Beauty

Under the motto “More quality for your life“, the LR Group with headquarters in Ahlen/Westphalia produces and markets various health and beauty products in around 28 countries. The range includes care and decorative cosmetics, dietary supplements and perfumes. LR Health & Beauty attaches great importance to the processing of premium raw materials. As most articles are manufactured at the Ahlen site, the company stands for top products "made in Germany". The processing of Aloe Vera has been one of the core competencies of LR Health & Beauty for more than 15 years. Only the valuable inside of the leaf is used for the products. With a volume of 12,000 tonnes of Aloe Vera leafs per year, LR is among the world’s largest manufacturers of Aloe Vera products. In Ahlen, the company has established the most modern Aloe Vera production site for Aloe Vera Drinking Gels in Europe. With 1,100 employees as well as thousands of registered sales partners and customers, LR is one of Europe’s leading direct sales enterprises. LR's strong market position is based above all on a high-quality product range and an attractive bonus and training plan which is unsurpassed in the industry. LR also established the LR Global Kids Fund e. V. which provides efficient and unbureaucratic support for deprived children and their families in many different countries around the world in cooperation with local institutions.

Exigo

Exigo is the leading global technology provider in the direct selling industry. Exigo supports 100 direct selling companies around the world, which include 12 of the 2019 DSN Global Top 100 direct sales companies. Exigo’s global clients operate in over 120 countries, 40 currencies and 30 languages.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

LR Health & Beauty
Almut Kellermeyer
Head of PR / Public Affairs
Tel: +49 2382 7060-114
Email: a.kellermeyer@LRworld.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye